

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**DINGDANG HEALTH TECHNOLOGY GROUP LTD.**

**叮噹健康科技集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 09886)**

**PROFIT WARNING**

This announcement is made by Dingdang Health Technology Group Ltd. (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended December 31, 2024 (the “**FY2024**”), the Company expects that the net loss for FY2024 will increase by more than 64% as compared to the net loss of approximately RMB230.87 million for the year ended December 31, 2023, which is mainly due to the fact that in consideration of the challenges in the performance of certain subsidiaries of the Company, the Company provided for impairment of goodwill allocated to the relevant subsidiaries and other intangible assets in excess of RMB203 million for FY2024. The aforesaid impairment is a one-off non-cash expense and is not expected to have any material impact on the overall operations of the Group.

To supplement the consolidated financial statements presented in accordance with IFRS, the Company also includes the adjusted net loss<sup>Note</sup> (non-IFRS measure) as an additional financial indicator, which is not required by, or presented in accordance with IFRS. According to the Company’s latest business operations and financial condition, the Company adjusts its adjusted net loss (non-IFRS measure) for FY2024 as net loss for the year to add back the impairment of goodwill and other intangible assets (excluding the income tax effects), amortization of other intangible assets arising from acquisitions (excluding the income tax effects) and share-based payments expenses.

The Company expects that the adjusted net loss for FY2024 will be narrowed by approximately RMB10 million to RMB30 million as compared to the Company's adjusted net loss of approximately RMB84.17 million for the year ended December 31, 2023.

*Note:* The Company believes that the adjusted net loss (non-IFRS measure) provides useful information to assist the Company's management in understanding and evaluating the consolidated results of operations. However, the presentation of the adjusted net loss (non-IFRS measure) may not be comparable to other similarly titled indicators presented. The use of adjusted net loss (non-IFRS measure) has limitations as an analytical tool, and Shareholders and potential investors should not consider it in isolation from, or as a substitute for analysis of, results of operations or financial conditions of the Company as reported under IFRS.

The Company is still in the process of finalizing the annual results for the Group for FY2024. The information contained in this announcement is only a preliminary assessment by the Board based on the figures and information currently available, and is not audited or reviewed by the auditor or the audit committee of the Company and may be subject to adjustments. Shareholders and potential investors of the Company should refer to and carefully read the annual results announcement of the Company for FY2024, which is expected to be published in March 2025.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**DINGDANG HEALTH TECHNOLOGY GROUP LTD.**  
**YANG WENLONG**  
*Chairman*

Hong Kong, February 21, 2025

*As of the date of this announcement, the executive Directors are Mr. YANG Wenlong, Mr. XU Ning, Mr. YU Lei, Mr. YU Qinglong and Mr. YANG Yibin, the non-executive Director is Ms. CAI Li, and the independent non-executive Directors are Mr. ZHANG Shouchuan, Dr. FAN Zhenhong and Mr. JIANG Shan.*